Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Alumis Inc. Common Stock

A company that transforms the lives of patients living with immune-mediated diseases using a precision approach to develop oral therapies.

Alumis

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.

We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. 

Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. 

Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.

Today we announced the pricing of our initial public offering: https://bit.ly/3zwhdvh #NasdaqListed

Today, we honor #Juneteenth, celebrating freedom, resilience, and progress. As we reflect on this important day in history, we’re committed to fostering diversity and inclusion at Alumis. #FreedomDay

Alumis’ clinical development team attended the EULAR - European Alliance of Associations for Rheumatology 2024 Congress earlier this month in Vienna! With the goal of driving progress in the clinical care of people with rheumatic diseases, the annual meeting brings together patients, health professionals, rheumatologists and industry partners to showcase the latest scientific breakthroughs in clinical, translational, and basic research. We were thrilled to be part of this meeting as we advance our #lupus clinical trial LUMUS! #EULAR2024

This #PrideMonth, we celebrate the vibrant LGBTQIA+ community and recognize their invaluable contributions to science and biotechnology. Together, we stand proud in our commitment to diversity, inclusion, and equality. #Pride2024

Did you know that women are disproportionately affected by #lupus? To learn more about lupus this #LupusAwarenessMonth, check out resources and information from @LupusResearch: https://lnkd.in/esmUVvvw

We are thrilled to announce our initial public offering, trading on Nasdaq under the ticker $ALMS! This achievement wouldn't have been possible without the relentless dedication of our incredible team, as well as the support of our Board of Directors and investors. Thank you to everyone who helped us reach this critical milestone in support of our mission to improve the lives of patients with immune-mediated diseases. #NasdaqListed

	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24
revenue
cost of revenue	120K -	120K 0%			758K -	760K 0.26%
gross profit	-120K -	-120K 0%			-758K -	-760K 0.26%
selling and marketing expenses
general and administrative expenses	4.22M -		5.97M -	5.53M 7.44%	5.63M 1.90%		10.57M -
selling general and administrative expenses	4.22M -	4.78M 13.02%	5.97M 25.05%	5.53M 7.44%	5.63M 1.90%	7.58M 34.50%	10.57M 39.60%
research and development expenses	32.31M -	32.73M 1.28%	37.79M 15.46%	34.60M 8.42%	41.20M 19.07%	47.80M 16.02%	87.82M 83.71%
other expenses	-12K -				-15K -
cost and expenses	36.66M -	37.62M 2.63%	43.76M 16.31%	40.13M 8.29%	47.59M 18.59%	56.14M 17.96%	98.40M 75.27%
operating expenses	36.54M -	37.50M 2.64%	43.76M 16.68%	40.13M 8.29%	46.84M 16.70%	55.38M 18.24%	98.40M 77.68%
interest expense
ebitda	-36.54M -	-37.50M 2.64%	-43.44M 15.83%	-39.41M 9.29%	-46.84M 18.85%	-55.38M 18.24%	-97.58M 76.21%
operating income	-36.66M -	-37.62M 2.63%	-43.76M 16.31%	-40.13M 8.29%	-47.59M 18.59%	-56.14M 17.96%	-98.40M 75.27%
depreciation and amortization	120K -	120K 0%	318K 165%	726K 128.30%	758K 4.41%	760K 0.26%	814K 7.11%
total other income expenses net	633K -	1.33M 110.74%	382K 71.36%	832K 117.80%	-2.26M 371.15%	-368K 83.69%	5.28M 1,535.33%
income before tax	-36.03M -	-36.29M 0.73%	-43.38M 19.53%	-39.30M 9.40%	-49.85M 26.84%	-56.51M 13.36%	-93.12M 64.79%
income tax expense
net income	-36.03M -	-36.29M 0.73%	-43.38M 19.53%	-39.30M 9.40%	-49.85M 26.84%	-56.51M 13.36%	-93.12M 64.79%
weighted average shs out	9.34M -	51.84M 455.09%	38.41M 25.91%		11.08M -	54.40M 391.00%	53.75M 1.20%
weighted average shs out dil	9.34M -	51.84M 455.09%	38.41M 25.91%		11.08M -	54.40M 391.00%	53.75M 1.20%
eps	-3.86 -	-0.70 81.87%	-1.13 61.43%	0 100%	-4.50 Infinity%	-1.04 76.89%	-1.73 66.35%
epsdiluted	-3.86 -	-0.70 81.87%	-1.13 61.43%	0 100%	-4.50 Infinity%	-1.04 76.89%	-1.73 66.35%

ALMS

COM:ALUMIS

Alumis

Last Close

9.44

22/11 21:00

Market Cap

668.34M

Beta: -

Volume Today

115.52K

Avg: -

Preview